Phase 2 study of eribulin-gemcitabine combination therapy for previously treated advanced liposarcoma or leiomyosarcoma
Dr. Hyo Song Kim
Eribulin or gemcitabine monotherapy has been found to be moderately effective in soft-tissue sarcomas. A phase 2 study in South Korea evaluated the combination of eribulin and gemcitabine for previously treated advanced liposarcoma or leiomyosarcoma. The combination had promising activity and acceptable safety.
